Extract
We read with interest the letters by Tadolini et al. [1] and Stochino et al. [2] in a recent issue of the European Respiratory Journal, which summarise the first available evidence on tuberculosis (TB) and coronavirus disease 2019 (COVID-19) [3].
Abstract
It is important to recognise the impact of COVID-19 on TB care to mitigate its consequences. TB services have an urgent need to identify novel strategies to ensure the continuum of TB care at the time of the coronavirus pandemic. https://bit.ly/2OIKnwL
Footnotes
Conflict of interest: P. Magro has nothing to disclose.
Conflict of interest: B. Formenti has nothing to disclose.
Conflict of interest: V. Marchese has nothing to disclose.
Conflict of interest: M. Gulletta has nothing to disclose.
Conflict of interest: L.R. Tomasoni has nothing to disclose.
Conflict of interest: S. Caligaris has nothing to disclose.
Conflict of interest: F Castelli reports acting as a principle investigator of company-sponsored clinical trials in the field of HIV infection (ViiV Healthcare, GlaxoSmithKline, Gilead Sciences and Janssen Cilag).
Conflict of interest: A. Matteelli has nothing to disclose.
Support statement: This research was carried out as part of the European Health Program 2014–2020, project: “E-DETECT, early detection and integrated management of tuberculosis in Europe”. Funding was received from the European Commission (709624).
- Received July 7, 2020.
- Accepted July 15, 2020.
- Copyright ©ERS 2020
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.